CGTN
10.3.2021 14:26:12 CET | Business Wire | Press release
Britain's communications regulator Ofcom has been criticized for its decision to ban and fine China Global Television Network (CGTN) for political reasons.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210310005537/en/
A group of journalists, filmmakers and artists recently challenged Ofcom's "act of censorship" in an open letter published by the No Cold War campaign and the Morning Star.
"The decision by Ofcom to remove the broadcasting license of CGTN is an act of censorship which is not in the interests of Britain and its people," the open letter said, calling the move an "attack on free speech."
Ofcom revoked the license of CGTN to broadcast in the UK in early February on the grounds of its ultimate control and its political attributes. Beijing slammed the move as political repression against Chinese media.
In their letter, the signatories questioned Ofcom's justification for banning CGTN.
"Ofcom's justification for taking CGTN off air is that any holder of a broadcasting license in Britain must not be controlled by political bodies. However, this law is only selectively applied. Numerous private and state channels have clear political agendas or control – the BBC itself, for example, which had its staff vetted by MI5, has not had its broadcasting license revoked," it said.
The letter urged Ofcom to reverse its decision and reinstate CGTN's license.
CGTN committed to balanced reporting
A spokesperson for CGTN on Tuesday called on the British regulator to calmly listen to the opinions expressed in the letter and end its political crackdown on Chinese media.
The spokesperson said that as an international news channel, CGTN is committed to providing "accurate, timely and objective news and information with diverse and balanced views" for its global audiences.
"China is increasingly connected and engaged with the rest of the world including the UK," the spokesperson said in a statement. "It is our responsibility to present Chinese viewpoints and perspectives in our news reporting, which is what our viewers expect and is also in the interest of the public."
'The world should be able to hear China's voice'
In a separate statement on Tuesday, CGTN said it is disappointed with and firmly opposes Ofcom's latest sanction decisions and adjudications against it.
Ofcom on Monday fined CGTN 225,000 British pounds (about $310,933) for "breaching rules on fairness, privacy and due impartiality" just weeks after it stripped the network of its right to air in Britain.
"CGTN believes its coverage of the 2019 violent protests in the Hong Kong Special Administrative Region was fair, truthful and duly impartial," the statement said.
"As a news outlet from China, CGTN made it possible for global audiences to see and hear a more complete picture of events in Hong Kong by reporting on the voices opposing violence and destruction," it stressed. "The fact that CGTN has been sanctioned by Ofcom for its objective coverage of the event is unjust."
"It is in the public interest that the world should be able to hear China's voice and perspective and see the true picture more clearly," it added.
At a regular press briefing on Tuesday, Chinese Foreign Ministry spokesperson Zhao Lijian urged Ofcom and certain individuals to immediately cease engaging in political manipulation and correct their mistakes, slamming the move as "blatant political oppression."
View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005537/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
